TABLE 1.
Baseline demographics
| Parameter | Participants in overall population (n = 19) | Participants in evaluable pharmacokinetic population (n = 15) a |
|---|---|---|
| Age (y) | ||
| Mean (SD) | 33.3 (9.1) | 30.1 (7.0) |
| Range | 22.0–53.0 | 22.0–46.0 |
| Sex, n (%) | ||
| Female | 10 (53) | 7 (47) |
| Male | 9 (47) | 8 (53) |
| Body mass index (kg/m2) | ||
| Mean (SD) | 27.2 (3.3) | 26.9 (2.9) |
| Range, min‐max | 21.4–33.1 | 21.4–31.1 |
| Height, mean (SD), cm | 171.1 (10.2) | 171.8 (9.0) |
| Weight, mean (SD), kg | 79.4 (11.5) | 79.1 (9.0) |
| Race and ethnicity, n (%) | ||
| Not Hispanic and not Latino | 19 (100) | 15 (100) |
| Asian | 1 (5) | 1 (7) |
| Black and African American | 6 (32) | 5 (33) |
| White | 12 (63) | 9 (60) |
SD, standard deviation.
a
Four participants did not have evaluable pharmacokinetic data: 2 withdrew before receiving intramuscular injection; 1 had injection maladministration into the retroperitoneal cavity; and 1 was hospitalized for non–study drug‐related serotonin syndrome.